fig6

Figure 6. MSC-EVs are enriched with immune-regulatory proteins and attenuate IL-17-mediated inflammation. (A) GO enrichment analysis of significantly upregulated proteins in MSC-EVs. The Y-axis represents immune-related GO terms, and the X-axis represents BgRatio; (B) ELISA analysis of IL-17 in serum (n = 6); (C) IL-17 (green) and DAPI (blue) co-immunostaining of Sham, BDL and EV treatment groups in liver and kidney (scale bar = 100 μm); (D) Quantification of percentage area of IL-17 in the liver (n = 6); (E) Quantification of percentage area of IL-17 in the kidney (n = 6); (F) qRT-PCR analysis of the mRNA expression levels of IL-17 in the liver (n = 3); (G) qRT-PCR analysis of the mRNA expression levels of IL-17 in the kidney (n = 3). Data were analyzed by one-way ANOVA with Tukey’s post hoc test. Data are presented as mean ± SD. ^**P < 0.01; ^***P < 0.001. MSC-EVs: Mesenchymal stem cell-derived extracellular vesicles; GO: Gene Ontology; ELISA: enzyme-linked immunosorbent assay; IL-17: interleukin-17; DAPI: 4’,6-diamidino-2-phenylindole; qRT-PCR: quantitative real-time polymerase chain reaction; mRNA: messenger RNA; BDL: bile duct ligation; ANOVA: analysis of variance; SD: standard deviation.